Hyloris Pharmaceuticals SA (EBR:HYL)

Hyloris Pharmaceuticals Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	8.74	13.78	23.59	30.41	33.46	50.01
Short-Term Investments	-	-	-	-	10.47	0.53
Cash & Short-Term Investments	8.74	13.78	23.59	30.41	43.93	50.54
Cash Growth	-54.32%	-41.62%	-22.40%	-30.78%	-13.09%	-21.53%
Accounts Receivable	6.54	5.15	4.86	3.57	4.13	2.32
Other Receivables	0.12	0.36	0.51	0.24	-	-
Receivables	7.04	6.01	5.92	4.31	4.13	2.32
Inventory	0.05	0.05	-	-	-	-
Prepaid Expenses	0.19	0.13	0.19	0.59	1.75	1.1
Other Current Assets	-	-0	-	-	-	-
Total Current Assets	16.01	19.96	29.71	35.31	49.8	53.96
Property, Plant & Equipment	1.57	1.69	1.99	2.15	1.06	0.3
Long-Term Investments	3.43	3.54	3.75	4.8	4.95	4.53
Other Intangible Assets	5.96	3.35	1.76	3.83	1.81	1.85
Long-Term Accounts Receivable	2.48	2.48	2.05	1.59	1.31	1.71
Long-Term Deferred Charges	0.35	2.34	2.08	-	1.68	1.09
Other Long-Term Assets	-0	0	-0	-	0.12	-
Total Assets	29.8	33.36	41.34	47.68	60.73	63.44

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	2.4	4.27	3.17	3.2	2.3	2.62
Accrued Expenses	0.27	0.35	0.26	0.12	0.07	0.08
Current Portion of Long-Term Debt	-	-	-	-	-	8.62
Current Portion of Leases	0.35	0.36	0.33	0.24	0.14	0.07
Current Income Taxes Payable	-	-	-	-	-	0.35
Current Unearned Revenue	0.04	0.08	-	0.01	-	-
Other Current Liabilities	0.26	0.08	3.41	3.2	3.26	3.25
Total Current Liabilities	3.32	5.13	7.16	6.76	5.77	14.98
Long-Term Debt	0.03	0.05	0.1	-	-	-
Long-Term Leases	1.08	1.19	1.39	1.51	0.75	0.11
Other Long-Term Liabilities	0.43	0.5	0.54	0.34	0.3	0.3
Total Liabilities	4.86	6.88	9.19	8.61	6.82	15.39

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.14	0.14	0.14	0.14	0.14	0.13
Additional Paid-In Capital	121.51	121.51	121.51	121.51	121.51	103.69
Retained Earnings	-94.68	-92.8	-86.47	-80.76	-65.38	-54.81
Comprehensive Income & Other	-2.03	-2.37	-3.04	-1.82	-2.36	-0.96
Total Common Equity	24.94	26.48	32.14	39.07	53.91	48.06
Shareholders' Equity	24.94	26.48	32.14	39.07	53.91	48.06
Total Liabilities & Equity	29.8	33.36	41.34	47.68	60.73	63.44

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1.46	1.61	1.82	1.75	0.89	8.79
Net Cash (Debt)	7.27	12.17	21.78	28.66	43.04	41.75
Net Cash Growth	-58.37%	-44.14%	-24.00%	-33.42%	3.09%	-25.39%
Net Cash Per Share	0.26	0.43	0.78	1.02	1.58	1.62
Filing Date Shares Outstanding	26.79	28	28	28	28	25.83
Total Common Shares Outstanding	26.79	28	28	28	28	25.83
Working Capital	12.69	14.83	22.55	28.55	44.03	38.98
Book Value Per Share	0.93	0.95	1.15	1.40	1.93	1.86
Tangible Book Value	18.98	23.13	30.39	35.24	52.1	46.2
Tangible Book Value Per Share	0.71	0.83	1.09	1.26	1.86	1.79

Data Source: S&P Global Market Intelligence Last updated: Sep 24, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 10, 2026

Data Sources Report a data error